Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00847483 · ClinicalTrials.gov registry record · Phase 4
Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 375
- Enrollment target
NCT00847483 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 375 participants.
The verdict
NCT00847483, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 375 participants
- Enrollment target
Study Summary
Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost
Interventions
- DRUG latanoprost 0.005% ophthalmic solution
- DRUG Travoprost 004% sterile ophthalmic solution
- DRUG Bimatoprost .03% sterile ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2002-01 |
| Est. Completion | 2002-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00847483
The ClinicalTrials.gov registry entry for NCT00847483 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which latanoprost 0.005% ophthalmic solution is the first listed.
NCT00847483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00847483 about?
NCT00847483 is a clinical study titled "Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US". Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost
What is the current status of trial NCT00847483?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 375 participants. The study started on 2002-01. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00847483?
The interventions under investigation include: latanoprost 0.005% ophthalmic solution (DRUG), Travoprost 004% sterile ophthalmic solution (DRUG), Bimatoprost .03% sterile ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00847483?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.